Status:

TERMINATED

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Lead Sponsor:

Spanish Breast Cancer Research Group

Collaborating Sponsors:

Novartis

Conditions:

Breast Cancer

Neoplasm Metastasis

Eligibility:

FEMALE

18-70 years

Phase:

PHASE3

Brief Summary

This is an open-label, randomized, multicenter phase III trial to assess the efficacy of early administration of zoledronate versus observation in delaying bone-related symptoms in metastatic breast c...

Detailed Description

Patients will be randomised to receive 4 mg zoledronate every 3-4 weeks versus observation until bone-related symptoms appear, or up to 12 months. One hundred twelve patients per treatment arm will be...

Eligibility Criteria

Inclusion

  • Written informed consent.
  • Age \>= 18 years old.
  • Metastatic breast cancer patients with lytic, sclerotic or mixed bone lesions.
  • Non-symptomatic bone lesions, defined as pain absence, lack of bone complications (fracture, hypercalcemia, Central Nervous System (CNS) compression), no need of analgesic chronic administration for bone disease.
  • A maximum of two chemotherapy lines for metastatic disease.
  • A maximum of two hormone therapy lines for metastatic disease.
  • Normal, minimally altered renal function (serum creatinine \< 1.5 x Upper Normal Limit (UNL)).
  • Normal serum calcium levels.
  • Performance status 0,1 (World Health Organization (WHO)).
  • Negative pregnancy test before study recruitment.

Exclusion

  • Previous treatment with bisphosphonates or raloxifene in the 30 days prior to randomization.
  • Metastasis in CNS.
  • History of hypersensitivity to bisphosphonates.
  • Pregnant or lactating women.
  • Third chemotherapy line for metastatic disease.
  • Third hormone therapy line for metastatic disease.
  • Males.

Key Trial Info

Start Date :

August 29 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 22 2007

Estimated Enrollment :

97 Patients enrolled

Trial Details

Trial ID

NCT00130494

Start Date

August 29 2002

End Date

October 22 2007

Last Update

April 16 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Spanish Breast Cancer Research Group (GEICAM)

San Sebastián de los Reyes, Madrid, Spain, 28700